Ambeed 大中华区 CN | ZH

中文 - ZH English - EN

Ambeed.cn

搜索

关键字搜索批量搜索

首页 收藏 购物车0
首页 / 抑制剂/激动剂 / 神经信号通路 / MAO / Safinamide/沙芬酰胺

Safinamide/沙芬酰胺 {[allProObj[0].p_purity_real_show]}

货号：A189271 同义名： FCE 26743; EMD 1195686

Safinamide 是一种可逆且高度选择性的 MAO-B 抑制剂（IC50 = 98 nM），兼具阻断钠和钙离子通道、抑制谷氨酸释放以及阻断多巴胺和血清素再摄取的多重机制，常被用于帕金森病的研究。

Safinamide/沙芬酰胺 化学结构 CAS号：133865-89-1
Safinamide/沙芬酰胺 化学结构
CAS号：133865-89-1
Safinamide/沙芬酰胺 3D分子结构
CAS号：133865-89-1
Safinamide/沙芬酰胺 化学结构 CAS号：133865-89-1
Safinamide/沙芬酰胺 3D分子结构 CAS号：133865-89-1
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePriceInt(item.pr_rmb, 1,1) ]}

{[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}

{[ getRatePriceInt(item.pr_rmb, 1,1) ]}

{[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} 		{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} 现货 1周 咨询 - +
购物车0 收藏 询单

Safinamide/沙芬酰胺 纯度/质量文件 产品仅供科研

货号：A189271 标准纯度： {[allProObj[0].p_purity_real_show]}
批次查询： 批次纯度:

全球学术期刊中引用的产品

• Nature, 2025, 645, 793-800. Ambeed. [ A201204 , A444152 , A344107 , A952055 ]
• Cell, 2025. Ambeed. [ A122167 ]
• Science, 2025, 387(6729): eadp5637. Ambeed. [ A875019 ]
• Sig. Transduct. Target. Ther., 2025, 10, 257. Ambeed. [ A104916 ]
• Nat. Nanotechnol., 2025. Ambeed. [ A243018 , A1216705 , A522597 , A125401 , A1355641 ]
更多 >
产品名称 MAO ↓ MAO-A ↓ MAO-B ↓ 其他靶点 纯度
Sennoside A ++

MAO, IC50: 17 μM

 		98%+
Glycyrrhizic acid ++++

MAO, IC50: 0.16 μM

 		80% HPLC
Rasagiline ++++

MAO-A, IC50: 412 nM

 		++++

MAO-B, IC50: 4.43 nM

 		97%
Isatin ++

MAO, IC50: 15 μM

 		+

MAO-A, IC50: 58 μM

 		++

MAO-B, IC50: 14 μM

 		98%
Paeonol +

MAO-A, IC50: 54.6 μM

 		+

MAO-B, IC50: 42.5 μM

 		98%
Tranylcypromine HCl +++

MAO-A, IC50: 11.5 μM

 		+++

MAO-B, IC50: 7 μM

 		97%
Moclobemide +++

MAO-A (5-HT), IC50: 6.1 μM

 		99%+
Pargyline HCl ++

MAO-A, Ki: 13 μM

 		+++

MAO-B, Ki: 0.5 μM

 		99%+
Safinamide ++++

MAO-B, IC50: 98 nM

 		98%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Safinamide/沙芬酰胺 生物活性

靶点

  • MAO-B

    MAO-B, IC50:98 nM
描述 Glial cells contain two enzymes that metabolize biogenicamines: COMT and MAO. MAO, located in the outer mitochondrial membrane, occurs as two isozymes: A and B. MAO-A is predominantly found in the intestinal tract and, in the CNS, presynaptic neurons; MAO-B is mainly located in the brain, generally in glial cells near dopaminergic synapses. MAO-B regulates the free concentrations of biogenic amines in the synaptic cleft[3].Safinamide is a highly selective and reversible MAO-B inhibitor that produces an increase in extracellular levels of dopamine in the striatum[4]. The non-dopaminergic mechanism of action involves state- and use-dependent blockade of voltagegated sodium channels and modulation of N-type calcium channels, thereby inhibiting glutamate release[5]. In rats, safinamide was &5000-fold more potent in inhibiting MAO-B than MAO-A [6]. In humans, safinamide provided platelet MAO-B inhibition at doses of C0.5 mg/kg,but did not inhibit MAO-A enzyme activity at a dose of 10 mg/kg[7].Safinamide has demonstrated neuroprotective, neurorescuing, anti-inflammatory and tremorolytic properties in several animal models,and was shown to reduce the duration and intensity of levodopa-induced dyskinesia in parkinsonian monkeys[8]. in vitro , safinamide is not a substrate for the transporters P-glycoprotein, BCRP, OAT1B1, OAT1B3, OATP1A2 or OATP2B1. The metabolite safinamide acid is not a substrate for OCT2 or OAT1 but is a substrate for OAT3,although potential pharmacokinetic interactions are not likely to be clinically relevant. Safinamide acid does not inhibit OCT2, MATE1 or MATE2-K[9].

Safinamide/沙芬酰胺 细胞实验

Cell Line
Concentration Treated Time Description References
M17 neuronal cells 100 or 200 nM 24 hours To evaluate the effect of Safinamide on Aβ1-42 oligomer-induced oxidative stress. Results showed that Safinamide significantly reduced ROS production and restored GSH content. Bioengineered. 2022 Jan;13(1):1921-1930
M17 neuronal cells 100 or 200 nM 7 days To evaluate the effect of Safinamide on Aβ1-42 oligomer-induced cellular senescence. Results showed that Safinamide significantly reduced the number of SA-β-gal positive cells and restored telomerase activity. Bioengineered. 2022 Jan;13(1):1921-1930

Safinamide/沙芬酰胺 动物实验

Species
Animal Model
Administration Dosage Frequency Description References
Rat Sprague-Dawley rats Oral 10 mg/kg Single dose To study the pharmacokinetic properties of Safinamide in rats Front Pharmacol. 2023 Aug 28;14:1211383

Safinamide/沙芬酰胺 临床研究

NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT00627640 Idiopathic Parkinson's Disease Phase 3 Completed - -
NCT00642889 Parkinson's Disease Phase 3 Completed - -
NCT01028586 Idiopathic Parkinson's Disease Phase 3 Terminated(Trial is terminated... 展开 >> due to a company decision to return all rights for Safinamide back to Newron Pharmaceuticals) 收起 << - Switzerland ... 展开 >> Enquire Central Contact Geneva, Switzerland 收起 <<

Safinamide/沙芬酰胺 参考文献

[1]Binda C, Wang J, et al. Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs. J Med Chem. 2007 Nov 15;50(23):5848-52.

[2]Caccia C, Maj R, et al. Safinamide: from molecular targets to a new anti-Parkinson drug. Neurology. 2006 Oct 10;67(7 Suppl 2):S18-23.

[3] Bartl J,et al. Chronic monoamine oxidase-B inhibitor treatment blocks monoamine oxidase-A enzyme activity. J Neural Transm. 2014;121:379–83.

[4] Safinamide for Parkinson's disease. Drug Ther Bull. 2018 May;56(5):54-57.

[5] European Medicines Agency. Safinamide: summary of product characteristics. 2014.

[6] Caccia C, Maj R, Calabresi M, et al. Safinamide: from molecular targets to a new anti-Parkinson drug. Neurology. 2006;67(7 Suppl2):S18–23.

[7] Cattaneo C, Caccia C, Marzo A, et al. Pressor response to intravenous tyramine in healthy subjects after safinamide, a novel neuroprotectant with selective, reversible monoamine oxidase B inhibition. Clin Neuropharmacol. 2003;26(4):213–7

[8] Gregoire L, Jourdain VA, Townsend M, et al. Safinamide reduces dyskinesias and prolongs l-dopa antiparkinsonian effect in parkinsonian monkeys. Parkinsonism Relat Disord. 2013;19(5):508–14.

[9]European Medicines Agency. Xadago assessment report. 2014.

Safinamide/沙芬酰胺 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.31mL

0.66mL

0.33mL

16.54mL

3.31mL

1.65mL

33.08mL

6.62mL

3.31mL

Safinamide/沙芬酰胺 技术信息

CAS号133865-89-1
分子式C17H19FN2O2
分子量 302.34
SMILES Code C[C@H](NCC1=CC=C(OCC2=CC=CC(F)=C2)C=C1)C(N)=O
MDL No. MFCD00897036
别名 FCE 26743; EMD 1195686; PNU-15774E
运输蓝冰
InChI Key NEMGRZFTLSKBAP-LBPRGKRZSA-N
Pubchem ID 131682
存储条件

In solvent -20°C: 3-6个月 -80°C: 12个月

Pure form Keep in dark place, inert atmosphere, 2-8°C
溶解方案

DMSO: 105 mg/mL(347.29 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

请根据您的动物给药指南选择适当的溶解方案。
以下溶解方案都请先按照体外实验的方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议现用现配，当天使用； 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶
方案 一
方案 二

Tags: Safinamide | FCE 26743;EMD 1195686;PNU-15774E | MAO | AmBeed-信号通路专用抑制剂 | Safinamide/沙芬酰胺 纯度/质量文件 | Safinamide/沙芬酰胺 亚型比较 | Safinamide/沙芬酰胺 生物活性 | Safinamide/沙芬酰胺 临床数据 | Safinamide/沙芬酰胺 参考文献 | Safinamide/沙芬酰胺 实验方案 | Safinamide/沙芬酰胺 技术信息

AmBeed 相关网站 AmBeed.cn AmBeed.com
AmBeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
    • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    AmBeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质用途提供服务。

    尊敬的 AmBeed 客户您好，
    请您选择所在区域，我们将转接对应客服为您服务！

    热门区域

    A

    B

    C

    F

    G

    H

    J

    L

    N

    Q

    S

    T

    X

    Y

    Z

    热 A B C F G H J L N Q S T X Y Z